Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects

Phase 1 Completed 18 enrolled AbbVie

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetics and safety of multiple oral doses of ABT-450/ritonavir/ABT-267 and ABT-333 when co-administered under non-fasting conditions in healthy Chinese adult participants.

Timeline

Start: 2015-09
Primary completion: 2015-09
Completion: 2015-09

Publications

Zha J, Ding B, Wang H, Zhao W, Yu C, Alves K, Mobashery N, Luo Y, Menon RM. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients. Eur J Drug Metab Pharmacokinet. 2019 Feb;44(1):43-52. doi: 10.1007/s13318-018-0492-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ritonavir	Other / unclassified	100 mg	Oral
Subject	dasabuvir	Small molecule	250 mg	Oral
Subject	ombitasvir	Small molecule	25 mg	Oral
Subject	paritaprevir	Small molecule	150 mg	Oral

Indications

No indication recorded.